

Integrated Diagnostics Holdings Plc

1H 2025 Results

Tuesday, 2 September 2025

Integrated Diagnostics Holdings plc records impressive revenue growth of 42% in 1H 2025 with improving margins across the board

(London) — Integrated Diagnostics Holdings (“IDH,” “the Group,” or “the Company”), a leading provider of diagnostic services with operations in Egypt, Jordan, Nigeria, Saudi Arabia, and Sudan announced today its unaudited financial statements for the quarter and six-month period ended 30 June 2025. The Company reported revenue of EGP 3.5 billion in 1H 2025, representing a year-on-year expansion of 42% on the back of a 10% year-on-year rise in tests performed and a 29% year-on-year increase in average revenue per test. Meanwhile, the Group’s efforts to maintain a tight grip on costs saw IDH’s margins improve across the income statement. During the six-month period, IDH’s gross profit expanded 61% year-on-year with an associated margin of 42.0% versus 37.0% this time last year. Similarly, IDH’s adjusted EBITDA increased 78% versus 1H 2024, yielding a margin of 33.6%, seven percentage points above last year’s figure. Finally, IDH’s bottom-line came in at EGP 571 million in 1H 2025, up 19% year-on-year. When controlling for FX gains booked in both periods, IDH’s normalised¹ bottom-line more than doubled year-on-year, with an associated adjusted margin of 16.2% in 1H 2025 versus 7.3% this time last year.

On a three-month basis, IDH’s revenue stood at EGP 2.0 billion, up 48% versus the same three months of last year. Further down the income statement, IDH’s second quarter adjusted EBITDA stood at EGP 691 million, up 105% versus last year and with an associated margin of 35.3% in Q2 2025 versus 25.4% last year. Finally, IDH’s bottom-line for the quarter came in at EGP 326 million versus the EGP 78 million bottom line recorded this time last year.

In the final weeks of the second quarter, IDH’s Egyptian radiology subsidiary, Al Borg Scan, successfully completed a strategic acquisition of CAIRO RAY for Radiotherapy, a radiology and radiotherapy facility in East Cairo for a total consideration of EGP 400 million. The acquisition represents a landmark step forward in realizing the Company’s long-term vision of building an established radiology offering alongside its already market-leading pathology business.

Financial Results (IFRS)

EGP mn	Q2 2024	Q2 2025	Change	1H 2024	1H 2025	Change
Revenue	1,327	1,960	48%	2,498	3,543	42%
Cost of Sales	(831)	(1,101)	33%	(1,573)	(2,053)	31%
Gross Profit	497	859	73%	925	1,489	61%
Gross Profit Margin	37.4%	43.8%	6.4%	37.0%	42.0%	5.0 pts.
Operating Profit	215	556	159%	435	921	112%
Adjusted EBITDA²	338	691	105%	668	1,190	78%
Adjusted EBITDA Margin	25.4%	35.3%	9.8%	26.7%	33.6%	6.8 pts.
Net Profit	78	326	316%	480	571	19%
Net Profit Margin	5.9%	16.6%	10.7%	19.2%	16.1%	-3.1 pts.
Normalised Net Profit¹	83	360	335%	183	575	214%
Normalised Net Profit Margin	6.2%	18.4%	12.1%	7.3%	16.2%	8.9 pts.
Cash Balance³	1,254	1,708	36%	1,254	1,708	36%

Note: Throughout the document, percentage changes are calculated using the exact value (as per the Consolidated Financials) and not the corresponding rounded figure.

¹ Normalised net profit excludes FX gains from both periods.

² Adjusted EBITDA is calculated as operating profit plus depreciation and amortization. Adjusted EBITDA also excludes the EGP 10 million share-based payment made to Dr. Amid, Biolab’s CEO, during the current reporting period related to Biolab KSA. Additional information is available in notes 16 and 22 of the financial statements included at the end of this release.

³ Cash balance includes time deposits, treasury bills, current accounts, and cash on hand.


Key Operational Indicators⁴

EGP	1H 2024	1H 2025	Change
Branches	591	678 ⁵	+87
Patients ('000)	4,119	4,265	4%
Revenue per Patient (EGP)	606	831	37%
Tests ('000)	17,822	19,619	10%
Revenue per Test (EGP)	140	181	29%
Test per Patient	4.3	4.6	6%

Introduction

i. Financial Highlights

- IDH reported **consolidated revenue** of EGP 3,543 million in 1H 2025, up 42% year-on-year. Growth was supported by both a 10% rise in test volumes for the six-month period coupled with a 29% year-on-year rise in average revenue per test. On a quarterly basis, consolidated revenue reached EGP 1,960 million, up 48% from the second quarter of last year.



- Gross profit** recorded EGP 1,489 million in 1H 2025, up 61% year-on-year and with a gross profit margin (GPM) of 42.0% versus 37.0% this time last year. Improved gross profitability comes as a direct result of the Company's continued focus on cost optimisation. More specifically, during the period IDH saw its raw material as a share of revenue decline to 19.6% in 1H 2025 from 21.5% last year. Similarly, direct salaries and wages as a share of revenue declined to 19.1% from 19.5% in 1H 2024. On a quarterly basis, gross profit recorded EGP 859 million, up 73% year-on-year and yielding a GPM of 43.8% in Q2 2025 versus 37.4% last year.
- Adjusted EBITDA⁶** stood at EGP 1,190 million in 1H 2025, an increase of 78% versus the same period of last year. IDH's adjusted EBITDA margin recorded 33.6% in 1H 2025 up from 26.7% last year. Improved EBITDA profitability came on the back of better gross profitability coupled with a substantial decline in SG&A expenditures as a share of revenue which stood at 15% in 1H 2025 versus 20% last year. On a quarterly basis, adjusted EBITDA came in at EGP 691 million in Q2 2025, 105% above last year's second quarter figure. Adjusted EBITDA margin for the quarter recorded 35.3% versus 25.4% in Q2 2024.
- Net profit** came in at EGP 571 million in 1H 2025, up 19% from last year's bottom-line figure. Net profit margin (NPM) came in at 16.1% in 1H 2025 versus 19.2% last year. It is important to note that controlling for FX gains in both periods,

⁴ Key operational indicators are calculated based on revenue for the periods of EGP 3,543 million and EGP 2,498 million for 1H 2025 and 1H 2024, respectively.

⁵ IDH rolled out 85 new branches in Egypt, one new branch in Jordan, and re-opened a branch in Sudan over the past 12-month period. It is important to note that due to the ongoing conflict in Sudan, only one of IDH's 18 branches in the country is currently operating (reopened in Q3 2024).

⁶ Adjusted EBITDA is calculated as operating profit plus depreciation and amortization. Adjusted EBITDA also excludes the EGP 10 million share-based payment made to Dr. Amid, Biolab's CEO, during the current reporting period.

IDH's normalised net profit posted an impressive 214% year-on-year expansion, with the Company's normalised⁷ net profit margin coming in at 16.2% in 1H 2025 versus 7.3% last year. On a three-month basis, IDH's net profit stood at EGP 326 million, up substantially from the EGP 78 million profit recorded in Q2 2024. NPM for the quarter stood at 16.6% versus 5.9% last year.

- The Board has approved a cash **dividend** of USD 10 million (USD 0.017 per share) with respect to the year ended 31 December 2024.

ii. Operational Highlights

- As at 30 June 2025, IDH's **branch network** stood at 678 branches, up 87 branches from the 591 branches as at 30 June 2024. Over the last twelve months, IDH has inaugurated 85 new locations in Egypt, one new branch in Jordan, and has reopened a branch in Sudan (the remaining 17 continue to be shut indefinitely).
- During 1H 2025, IDH conducted 19.6 million **tests** across its geographies, up 10% year-on-year supported by growing volumes across all its markets (excluding Sudan where operations remain largely on hold). It is important to highlight IDH's success in growing test volumes despite the strategic price adjustments introduced at the start of the year, showcasing that the Company's value proposition continues to be highly attractive to patients across its growing footprint.
- IDH's **average revenue per test** rose 29% year-on-year to reach EGP 181 in 1H 2025. Meanwhile, average revenue per patient reached EGP 831 in 1H 2025, up 37% versus the same period of last year.
- IDH served 4.3 million **patients** in the first half of 2025, an increase of 4% year-on-year. Meanwhile, in line with IDH's long-term value extraction strategy, the Company continued to grow its average test per patient metric, which in 1H 2025 reached a record-high of 4.6 tests versus 4.3 this time last year. The steady rise in average tests per patient highlights the efficacy of IDH's initiatives over the past several years, including its loyalty program introduced in FY 2021.

iii. Updates by Geography

- In **Egypt** (83.7% of total revenue in 1H 2025), IDH recorded a top-line of EGP 2,966 million in 1H 2025, up 43% year-on-year. Top-line growth was supported by rising test volumes (up 9% versus 1H 2024) and higher average revenue per test (up 31% year-on-year).
- IDH's **Jordanian** subsidiary, Biolab (13.9% of total revenues in 1H 2025), reported revenue in local currency terms of JOD 7.0 million in 1H 2025, up 7% year-on-year. Revenue growth for the period was supported by a sustained 21% year-on-year rise in test volumes, boosted by a promotional campaign launched by Biolab during the six-month period. In EGP terms, Biolab saw revenue for the first half grow 28% year-on-year to EGP 493 million.
- In **Nigeria** (1.6% of total revenues in 1H 2025), Echo-Lab recorded revenue of NGN 1,768 million, up 38% from last year's first half figure. Increased revenue came on the back of a 3% year-on-year rise in test volumes coupled with a 34% year-on-year rise in average revenue per test in Naira terms as Echo-Lab continued to adjust prices to keep up with inflation in the country. In EGP-terms, revenue in Nigeria grew 49% year-on-year to EGP 58 million in 1H 2025. It is important to note that after having turned EBITDA positive in Q1 2025, IDH Nigerian subsidiary has continued to deliver positive EBITDA results on a half-year basis.
- Biolab KSA, IDH's newest venture in **Saudi Arabia** (0.7% of total revenues in 1H 2025), reported revenue of SAR 1.9 million in 1H 2025. During the second quarter of the year, the venture continued its steady ramp up with revenue in Q2 2025 standing 31% above revenue in the first three months of the year. Biolab KSA's May performance was particularly noteworthy when no holidays impacted patient traffic. IDH views the Saudi Arabian market as an important driver of future growth due to the market's large, growing, and increasingly health-conscious population which is looking for access to high-quality diagnostic services from a currently highly fragmented market. To capitalise on the strong momentum enjoyed in the Kingdom, Biolab KSA has inaugurated its third branch in early July of this year, taking the total operational network up to three branches. Over the coming months, IDH plans to launch three additional branches in the country (taking the total up to six), and leverage its expanded ownership stake⁸ to further accelerate growth at its newest geography.
- In Q3 2024, IDH reopened one branch in **Sudan** after temporarily shutting down all branches earlier in the year. It is worth highlighting that the remaining 17 branches remain closed indefinitely as the civil conflict in the country continues.

⁷ Normalised net profit excludes FX gains from both periods.

⁸ In December 2024, IDH announced the purchase of Izhoor's entire 49% stake in the venture for USD 3.2 million, bringing IDH's effective stake in Biolab KSA to 100% (79% controlled by IDH and 21% by its Jordanian subsidiary Biolab). It is worth noting that Biolab KSA was originally launched as a joint venture between IDH (30%), Biolab (21%), and Izhoor Holding Medical Company (49%) in January 2024.

iv. Management Commentary

Commenting on the Group's 1H 2025 performance, IDH Chief Executive Officer, Dr. Hend El-Sherbini, said: "At the halfway point of what has thus far been a very remarkable year, we are pleased to report another strong set of financial and operational results which build on our momentum from earlier in the year and on the improving operating conditions at home and across our regional footprint. The results achieved in the first six months of 2025 highlight once more the effectiveness of our growth and investment strategies which are enabling us to capture broad-based growth across our markets while making high-quality diagnostic services increasingly accessible to patients across our footprint.

During 1H 2025, we recorded consolidated year-on-year revenue growth of 42%, with our top-line reaching a record EGP 3.5 billion for the period. Growth was supported by noteworthy performances reported across both our more established Egyptian and Jordanian markets as well as encouraging results from our newer geographies of Nigeria and Saudi Arabia.

At home, we continue to invest significantly to maintain our leadership position and remain the go-to provider for patients nationwide. During the first six months of the year, we opened up 49 new locations to better serve patients within and outside Greater Cairo. Our efforts have delivered immediate results with test and patient volumes rising 9% and 3% year-on-year, respectively, and our top-line reaching EGP 3.0 billion, up 43% versus 1H 2024. Similar to Egypt, in Jordan revenue posted solid year-on-year growth in both EGP and JOD terms supported by a promotional campaign organised by Biolab which saw test volumes for the period grow an impressive 21% versus last year. In a market where volume driven growth is key for long-term sustainability, we were very pleased to see Biolab's strategy pay off so successfully. In Nigeria, Echo-Lab is now firmly EBITDA positive, a direct result of our revamped turnaround strategy kicked off last year. We are excited for our Nigerian subsidiary to build on the progress made thus far and fully capture the vast upside offered by the local radiology market. Finally, in our newest market of Saudi Arabia, the ramp up continues as planned. During the second quarter of the year, we saw Biolab KSA's revenue in local currency terms grow a remarkable 31% quarter-on-quarter, to surpass the SAR 1 million mark. We were particularly pleased with the venture's performance during May, when no national holidays impacted patient volumes. This leaves us optimistic for Biolab KSA's second half performance, which we are confident will set the venture up for long-term success. On this front, in early July we launched the venture's third location in the country. This is the first of four branch inaugurations planned for the year as Biolab KSA continues to build on the positive momentum enjoyed in its first 18 months of operations.

As always, a key focus for IDH remains driving profitable growth with our first half results pointing to widespread improvements across all key metrics. More specifically, during 1H 2025 we saw our gross profit margin expand five percentage points versus last year and our EBITDA margin expand seven percentage points compared to 1H 2024. These remarkable improvements come as we continue to press ahead with our cost optimisation efforts, which have seen our cost of goods sold and our SG&A outlays as a share of revenue decline by a combined nine percentage points versus the first half of last year. Our bottom-line profitability has also displayed sustained improvements when controlling for the substantial FX gains recorded in the comparable period of last year, with our adjusted net profit more than doubling year-on-year and yielding an associated margin of 16% in 1H 2025 versus 7% this time last year.

Heading into the second half of 2025 our priorities remain unchanged as we work to drive sustainable growth across our entire footprint while further improving our profitability metrics. In light of our strong first half performance and the steadily improving operating conditions across our markets, we see full-year revenue growth coming in above 30% in FY 2025. Meanwhile, we see profitability continuing to improve with our full-year EBITDA margin coming in north of 30%.

Finally, we are pleased to announce that our Board of Directors has approved the distribution of a cash dividend of USD 0.017 per share (USD 10 million in total) to shareholders. This decision follows a careful assessment of market conditions and the Company's cash flow needs for strategic investments, a review which led to the postponement of this decision earlier in the year. The Board is confident that the Company's strong financial performance in the first half of 2025 and its robust liquidity position now support this distribution, reflecting our commitment to delivering shareholder value."

– End –

Analyst and Investor Call Details

An analyst and investor call will be hosted at 13:00 pm (UK) | 15:00 (Egypt) on Monday, 15 September 2025. You can learn more details and register for the call by clicking on the [link](#).

For more information about the event, please contact: amoataz@EFG-HERMES.com

About Integrated Diagnostics Holdings (IDH)

IDH is a leading diagnostics services provider in the Middle East and Africa offering a broad range of clinical pathology and radiology tests to patients in Egypt, Jordan, Nigeria, Saudi Arabia, and Sudan. The Group's core brands include Al Borg, Al Borg Scan and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Echo-Lab (Nigeria), Ultralab and Al Mokhtabar Sudan (both in Sudan), and Biolab KSA (Saudi Arabia). With over 40 years of experience, a long track record for quality and safety has earned the Company a trusted reputation, as well as internationally recognised accreditations for its portfolio of over 3,000 diagnostics tests. From its base of 628 branches as of 31 December 2024, IDH served over 8.9 million patients and performed more than 39.2 million tests in 2024. IDH will continue to add laboratories through a Hub, Spoke and Spike business model that provides a scalable platform for efficient expansion. Beyond organic growth, the Group targets expansion in appealing markets, including acquisitions in the Middle Eastern, African, and East Asian markets where its model is well-suited to capitalise on similar healthcare and consumer trends and capture a significant share of fragmented markets. IDH has been a Jersey-registered entity (i) whose shares are admitted to the equity shares (transition) category (previously, the standard listing segment) of the Official List of the UK Financial Conduct Authority and admitted to trading on the main market for listed securities of the London Stock Exchange (ticker: IDHC) since May 2015.

Shareholder Information

LSE: IDHC.L

Bloomberg: IDHC:LN

Listed on LSE: May 2015

Shares Outstanding: 581,326,272

Contact

Tarek Yehia

Investor Relations Director

T: +20 (0)2 3332 1126 | M: +20 10 6882 6678 | tarek.yehia@idhcorp.com

Forward-Looking Statements


These results for the six-month period ended 30 June 2025 have been prepared solely to provide additional information to shareholders to assess the group's performance in relation to its operations and growth potential. These results should not be relied upon by any other party or for any other reason. This communication contains certain forward-looking statements. A forward-looking statement is any statement that does not relate to historical facts and events, and can be identified by the use of such words and phrases as "according to estimates", "aims", "anticipates", "assumes", "believes", "could", "estimates", "expects", "forecasts", "intends", "is of the opinion", "may", "plans", "potential", "predicts", "projects", "should", "to the knowledge of", "will", "would" or, in each case their negatives or other similar expressions, which are intended to identify a statement as forward-looking. This applies, in particular, to statements containing information on future financial results, plans, or expectations regarding business and management, future growth or profitability and general economic and regulatory conditions and other matters affecting the Group.

Forward-looking statements reflect the current views of the Group's management ("Management") on future events, which are based on the assumptions of the Management and involve known and unknown risks, uncertainties and other factors that may cause the Group's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. The occurrence or non-occurrence of an assumption could cause the Group's actual financial condition and results of operations to differ materially from, or fail to meet expectations expressed or implied by, such forward-looking statements.

The Group's business is subject to a number of risks and uncertainties that could also cause a forward-looking statement, estimate or prediction to differ materially from those expressed or implied by the forward-looking statements contained in this communication. The information, opinions and forward-looking statements contained in this communication speak only as at its date and are subject to change without notice. The Group does not undertake any obligation to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this communication.

Group Operational & Financial Review

i. Revenue and Cost Analysis




Consolidated Revenue

IDH continued to build on the strong momentum from the start of the year reporting top-line growth of 42% year-on-year in 1H 2025, with revenues reaching EGP 3,543 million for the six-month period. Top-line growth came on the back of both increased test volumes, which returned to solid year-on-year growth rising 10% versus last year, and higher average revenue per test in line with IDH's strategic price adjustments across several of its markets. The second quarter of the year saw a similar story with revenue coming in at EGP 1,960 million, up 48% versus the same three months of last year on the back of both rising volumes and price adjustments.

	Q2 2024	Q2 2025	Change	1H 2024	1H 2025	Change
Revenue (EGP mn)	1,327	1,960	48%	2,498	3,543	42%
Tests performed (mn)	9.1	11.1	21%	17.8	19.6	10%
Revenue per test (EGP)	145	177	22%	140	181	29%

Revenue by Patient Segment (1H 2025)



Revenue Analysis: Contribution by Patient Segment

Contract Segment (67% of Group revenue in 1H 2025)


At IDH's contract segment, revenue came in at EGP 2,383 million in 1H 2025, up 46% from the same six-month period of the previous year. Growth was dual-driven, with average revenue per test rising 33% year-on-year and test volumes up 10% versus the first half of last year.

Average tests per patient continued to grow, reaching a new record-high of 4.8 tests per patient in 1H 2025, up from 4.5 in 1H 2024 and 4.4 in 1H 2023. This steady rise has been supported by IDH's loyalty program, which was introduced back in 2021, and which has, since then, successfully increased tests demanded by patients visiting IDH's branches.

Walk-in Segment (33% of Group revenue in 1H 2025)

At IDH's walk-in segment, revenue recorded EGP 1,159 million in the first six months of the year, a year-on-year rise of 34%. During the period, test volumes rose 10% year-on-year while average revenue per walk-in test reached EGP 365, up 21% year-on-year. Meanwhile, average tests per patient at the segment also grew to reach a new high of 3.8 tests, versus 3.5 this time last year and 3.6 back in 1H 2023.

Tests by Patient Segment (1H 2025)




Detailed Segment Performance Breakdown

	Walk-in Segment			Contract Segment			Total		
	1H24	1H25	Change	1H24	1H25	Change	1H24	1H25	Change
Revenue (EGP mn)	866	1,159	34%	1,632	2,383	46%	2,498	3,543	42%
Patients ('000)	814	840	3%	3,305	3,424	4%	4,119	4,265	4%
% of patients	20%	20%		80%	80%				
Revenue per Patient (EGP)	1,064	1,380	30%	494	696	41%	606	831	37%
Tests ('000)	2,880	3,178	10%	14,942	16,441	10%	17,822	19,619	10%
% of Tests	16%	16%		84%	84%				
Revenue per Test (EGP)	301	365	21%	109	145	33%	140	181	29%
Test per Patient	3.5	3.8	7%	4.5	4.8	6%	4.3	4.6	6%

Revenue Analysis: Contribution by Geography

Revenue by Geography (1H 2025)



Egypt (83.7% of Group revenue in 1H 2025)

IDH's home and largest market, Egypt, revenue grew 43% year-on-year to reach EGP 2,966 million. Top-line growth was supported by a 9% year-on-year expansion in tests performed in the country coupled with a 31% rise in average revenue per test as IDH's strategic price adjustments continued to support growth.

Al-Borg Scan

IDH's rapidly growing radiology subsidiary, Al-Borg Scan, recorded revenue growth for the six-month period of 18% versus last year on the back of a 24% year-on-year rise in average revenue per scan. Meanwhile, scan volumes were down marginally as the year-to-date traffic continued to capture the larger-than-expected Ramadan-related slowdown seen in Q1 2025. Volumes in the second quarter returned to year-on-year growth as anticipated.


House Calls

During the first half of 2025, IDH's house call services remained a notable contributor to the Company's revenue in Egypt. More specifically, business generated by the service in the country made up 20% of Egypt's revenue in the period, well above the service's contribution prior to the Covid-19 pandemic. The remarkable contribution highlights the segment's growth potential and the efficacy of the Group's post-pandemic strategy.


Wayak

Meanwhile, Wayak, which leverages the Company's expanding patient database to develop electronic medical records and provide personalized services, reported revenue of EGP 19 million for the six-month period, up by 185% versus the comparable figure of last year. Revenue growth was driven by the 27% year-on-year growth in orders fulfilled, which reached 127 thousand in the six months ended 30 June 2025.

Egypt Revenue (EGP mn)




Al Borg Scan Revenue (EGP mn)




Detailed Egypt Performance Breakdown

	1H 2024	1H 2025	Change
Revenue (EGP mn)	2,069	2,966	43%
Pathology Revenue (contribution to Egypt's results)	1,966 (95.0%)	2,843 (95.9%)	45%
Radiology Revenue (contribution to Egypt's results)	104 (5.0%)	123 (4.1%)	18%
Tests performed (mn)	16.5	18.0	9%
Revenue per test (EGP)	125	164	31%


Jordan Revenue (EGP mn)




Jordan Revenue (JOD mn)




Nigeria Revenue (EGP mn)



Nigeria Revenue (NGN mn)



Saudi Arabia Revenue (1H 2025)



Jordan (13.9% of Group revenue in 1H 2025)

In IDH's second largest market, Jordan, Biolab reported revenue in local currency terms of JOD 7.0 million in 1H 2025, up a notable 7% year-on-year. Revenue growth for the period was supported by an impressive rise in test volumes which increased 21% versus the same six-month period of last year. Test volumes were boosted by a new promotional campaign launched by Biolab during the first quarter of this year. Meanwhile, average revenue per test in local currency terms declined 12% partially reflecting the impact of discounts offered to patients as part of the above-mentioned campaign. In EGP terms, Biolab reported revenue growth of 28% year-on-year to EGP 493 million.

Detailed Jordan Performance Breakdown

	1H 2024	1H 2025	Change
Revenue (EGP mn)	386	493	28%
Revenue (JOD mn)	6.5	7.0	7%
Tests performed (mn)	1.2	1.4	21%
Revenue per test (EGP)	334	352	5%

Nigeria (1.6% of Group revenue in 1H 2025)

Echo-Lab, IDH's Nigerian subsidiary, delivered revenue of NGN 1,768 million for the period, up 38% year-on-year. Revenue growth came on the back of a 38% year-on-year increase in average revenue per test in Naira terms as Echo-Lab continued to hike prices to keep up with inflation. Test volumes also grew 3% versus the comparable period of last year as easing inflation in the country supports a gradual recovery in patients' purchasing power. In EGP-terms, revenue in Nigeria grew an impressive 49% year-on-year to EGP 58 million in 1H 2025.

Saudi Arabia (0.7% of Group revenue in 1H 2025)

Biolab KSA, IDH's newest venture in Saudi Arabia, which began operations in Q1 2024 with one branch opening in January and another in March, reported revenue of SAR 1.9 million in 1H 2025. During the second quarter of the year, revenue surpassed the one million Riyals mark, expanding by a solid 31% versus the prior quarter. This continues to highlight the effectiveness of IDH's ramp up strategic in the market which aim to accelerate revenue growth and establish Biolab KSA as a key player in the currently large but high fragmented and relatively underpenetrated diagnostics market in the Kingdom.

Sudan

In Q3 2024, IDH reopened one branch in Sudan after temporarily shutting down all branches earlier this year. It is worth noting that the remaining 17 branches remain closed indefinitely as the civil conflict in the country continues.

Revenue Contribution by Country

	1H 2024	1H 2025	Change
Egypt Revenue (EGP mn)	2,069	2,966	43%
Pathology Revenue (EGP mn)	1,966	2,843	45%
Radiology Revenue (EGP mn)	104	123	18%
Egypt Contribution to IDH Revenue	82.8%	83.7%	
Jordan Revenue (EGP mn)	386	493	28%
Jordan Revenues (JOD mn)	6.5	7.0	7%
Jordan Revenue Contribution to IDH Revenue	15.4%	13.9%	
Nigeria Revenue (EGP mn)	39	58	49%
Nigeria Revenue (NGN mn)	1,284	1,768	38%
Nigeria Contribution to IDH Revenue	1.5%	1.6%	
Saudi Arabia Revenue (EGP mn)	4	25	496%
Saudi Arabia Revenue (SAR mn)	0.3	1.9	459%
Saudi Arabia Contribution to IDH Revenue	0.2%	0.7%	

Average Exchange Rate

	1H 2024	1H 2025	Change
USD/EGP	42.0	50.2	20%
JOD/EGP	59.1	70.7	20%
NGN/EGP	0.030	0.033	10%
SAR/EGP	11.2	13.4	19%
SDG/EGP	0.1	0.1	7%

Patients Served and Tests Performed by Country

	1H 2024	1H 2025	Change
Egypt Patients Served (mn)	3.9	4.0	3%
Egypt Tests Performed (mn)	16.5	18.0	9%
Jordan Patients Served (k)	172	181	5%
Jordan Tests Performed (k)	1,154	1,401	21%
Nigeria Patients Served (k)	59	55	-7%
Nigeria Tests Performed (k)	113	116	3%
Saudi Arabia Patients Served (k)	1	11	-
Saudi Arabia Tests Performed (k)	7	57	-
Total Patients Served (mn)	4.1	4.3	4%
Total Tests Performed (mn)	17.8	19.6	10%


Operational Branches by Country

	30 June 2024	30 June 2025	Change
Egypt	551	636	+85
Jordan	26	27	+1
Nigeria	12	12	-
KSA	2	2	-
Sudan	0	1	+1
Total	591	678	+87

Cost of Goods Sold

Breakdown

(1H 2025)



Cost of Goods Sold (COGS)

IDH's COGS for the six-month period recorded EGP 2,053 million, up 31% year-on-year. As a percentage of consolidate revenue, COGS declined to 58% from 63% in the same period of last year, driven by the ongoing Company-wide efforts to boost efficiencies and maintain a tight grip on expenses. More specifically, as a share of revenue, all four of IDH's main COGS categories declined versus 1H 2024, with the most notable contraction seen in the Company's raw material outlays as a share of revenue.

COGS Breakdown as a Percentage of Revenue

	1H 2024	1H 2025
Raw Materials	21.5%	19.6%
Wages & Salaries	19.5%	19.1%
Depreciation & Amortisation	8.5%	7.0%
Other Expenses	13.4%	12.3%
Total	63.0%	58.0%

Raw material costs (34% of consolidated COGS in 1H 2025) was the largest contributor to COGS for the period, having increased 29% year-on-year to reach EGP 693 million. As a share of revenue, raw material expenses declined notably to 19.6% in the first half of 2025 from 21.5% this time last year. The decline reflects IDH's proactive inventory management strategy which sees the Company leverage its scale to secure advantageous prices for its testing kits.


Wages and salaries, which include employee share of profits (33% share of consolidated COGS in 1H 2025), was the second largest contributor to IDH's total COGS during 1H 2025, recording EGP 676 million in 1H 2025, up 39% versus 1H 2024. Despite the year-on-year rise, as a percentage of revenue direct wages and salaries declined to 19.1% reflecting IDH's continued efforts to optimise headcount.

Direct Wages and Salaries by Region

	1H 2024	1H 2025	Change
Egypt (EGP mn)	358	515	44%
Jordan (EGP mn)	109	134	24%
Jordan (JOD mn)	911	944	4%
Nigeria (EGP mn)	11	13	17%
Nigeria (NGN mn)	176	182	4%
Saudi Arabia (EGP mn)	11	13	23%
Saudi Arabia (SAR k)	517	499	-3%

Direct depreciation and amortization costs (12% of consolidated COGS in 1H 2025) rose 17% year-on-year to EGP 249 million in 1H 2025. Rising depreciation expenses are linked to IDH's expansion efforts, which in the year to 30 June 2025 saw the Company add 85 new branches in its home market of Egypt. However, as a percentage of revenue, direct depreciation and amortization declined to 7.0% in 1H 2025 from 8.5% in 1H 2024.

Other expenses (21% of consolidated COGS in 1H 2025) recorded EGP 436 million in the first half of 2025, representing a year-on-year rise of 30%. Meanwhile, other expenses as a percentage of revenue stood at 12.3% down from the 13.4% figure reported this time last year. The main components making up other expenses during the past six months were repair and maintenance fees, hospital contracts, cleaning expenses, transportation, consulting fees, utilities, and license expenses.



Gross Profit

IDH reported a gross profit of EGP 1,489 million in 1H 2025, up 61% year-on-year. Gross profit margin (GPM) also improved remarkably to 42%, reflecting strong revenue growth and the above-mentioned broad-based declines in COGS as a share of revenue.


Selling, General, and Administrative (SG&A) Expenses

SG&A outlays for the six-month period stood at EGP 568 million, up just 16% year-on-year. As a share of revenue, SG&A made up 16.0% in 1H 2025 versus 19.6% this time last year. The rise in SG&A expenses versus the comparable six-month period of last year was mainly due to:

- **Indirect wages and salaries** reached EGP 263 million in 1H 2025, representing a 52% increase compared to the same period of the previous year. The increase reflects annual wage increases, the translation effect from Jordanian and Saudi Arabian salaries due to a weakened EGP, and new hires to support Biolab KSA's expansion who, for the most part, were onboarded in May 2024.
- **Advertising expenses** rose by 23% year-on-year as the Company doubled-down on its efforts to ramp-up its operations in Saudi Arabia and on its advertising and marketing efforts in its home market of Egypt.

Selling, General, and Administrative Expenses

EGP mn	1H 2024	1H 2025	Change
Wages & Salaries	173	263	52%
Accounting and Professional Fees	20	84	321%
Market – Advertisement expenses	78	97	23%
Other Expenses – Operation	172	96	-44%
Depreciation & Amortisation	21	20	-6%
Impairment Loss on Trade and Other Receivable	17	18	3%
Travelling and Transportation Expenses	9	16	79%
Impairment in Inventory	0	1	-
Provision No Longer Required	0	0	-
Provision for End of Service	0	1	-
Provision for Legal Claims	0	1	-
Other Income	-1	-27	-
Total	490	568	16%




Adjusted EBITDA⁹

IDH reported an adjusted EBITDA of EGP 1,190 million in 1H 2025, up 78% versus the same period of last year. Similarly, adjusted EBITDA margin also posted an impressive expansion, reaching 34% in 1H 2025 versus just 27% this time last year. Improved EBITDA profitability reflects the previously mentioned improvement at the gross margin level coupled with a remarkable decline in SG&A as a share of revenue for the period. The sustained declines seen in both COGS and SG&A as a share of revenue come as a direct result of the Company's cost control measures implemented across all facets of its operations over the past twelve months. The highlight from the first half of 2025 has undoubtedly been the completion of Echo-Lab's turnaround, with the subsidiary posting positive EBITDA results starting with the first quarter of this year.

⁹ Adjusted EBITDA is calculated as operating profit plus depreciation and amortization. Adjusted EBITDA also excludes the EGP 10 million share-based payment made to Dr. Amid, Biolab's CEO, during the current reporting period related to Biolab KSA. Additional information is available in notes 16 and 22 of the financial statements included at the end of this release.

Adjusted EBITDA by Region (1H 2025)



EBITDA by Country

In **Egypt**, IDH recorded an adjusted EBITDA¹⁰ of EGP 1,072 million, up 62% year-on-year and with an associated margin of 36% versus 32% in 1H 2024. Improved EBITDA profitability came on the back of both enhanced gross profitability in the country (GPM at 46% in 1H 2025 versus 41% in 1H 2024), combined with optimised SG&A expenses for the six-month period.

In **Jordan**, Biolab's EBITDA was up 34% year-on-year to reach JOD 2.0 million in the first half of the year. EBITDA margin for the period recorded 29%, up from last year's 23% margin. In EGP terms, EBITDA recorded EGP 142 million, up 60% year-on-year, partially reflecting the translation effect from a weaker EGP.


In **Nigeria**, Echo-Lab turned EBITDA positive in Q1 2025, with EBITDA for the first half of the year standing at NGN 40 million versus an EBITDA loss of NGN 426 million this time last year. The venture's EBITDA margin stood at 2% for the period. In EGP terms, EBITDA recorded EGP 1.3 million in 1H 2025 versus an EBITDA loss of EGP 13.5 million in 1H 2024.

In **Saudi Arabia**, EBITDA losses amounted to SAR 2.7 million (EGP 26 million) as the business remains in its ramp up phase. EBITDA losses were down year-on-year compared to the SAR 6.1 million booked this time last year.

Regional Adjusted EBITDA in Local Currency

	1H 2024	1H 2025	Change
Egypt Adjusted EBITDA (EGP mn)	663	1,072	62%
Margin	32.0%	36.1%	4.1 pts.
Jordan Adjusted EBITDA (JOD mn)	1.5	2.0	34%
Margin	22.9%	28.8%	5.9 pts.
Nigeria Adjusted EBITDA (NGN mn)	(426)	40	-
Margin	-33.2%	2.3%	35.4 pts.
Saudi Arabia Adjusted EBITDA (SAR mn)	(6.1)	(2.7)	-56%
Margin	-	-140%	-

Interest Expense (EGP mn)



Interest Income / Expense

IDH's **interest income** came in at EGP 107 million in 1H 2025, up 96% year-on-year and reflecting primarily higher interest income reflects higher interest rates in Egypt. It is worth noting that in April 2025, the Central Bank of Egypt (CBE) cut interest rates for the first time since November 2020 following multiple positive inflation readings since the start of the year. Following rate cuts in April, May and August 2025 for a cumulative 525 basis points, the main operations rate in Egypt currently stands at 22.5%.

Interest expense¹¹ recorded EGP 97 million in 1H 2025, up just 9% year-on-year. The rise in interest expenses was mainly driven by:

- Higher interest on lease liabilities related to IFRS 16 due to the addition of new branches to IDH's network.
- Higher bank charges which increased to EGP 11 million in 1H 2025 from EGP 6 million this time last year reflecting higher revenue for the period.

¹⁰ Adjusted EBITDA is calculated as operating profit plus depreciation and amortization. Adjusted EBITDA also excludes the EGP 10 million share-based payment made to Dr. Amid, Biolab's CEO, during the current reporting period related to Biolab KSA. Additional information is available in notes 16 and 22 of the financial statements included at the end of this release.

¹¹ Interest expenses on medium-term loans include EGP 9 million (EGP 11 million in 1H 2024) related to the Group's facility with Kuwait Finance House (KFH) – formerly Ahli United Bank (AUB).

It is worth noting that interest expense on borrowing during the six months of the year declined 13% year-on-year to EGP 11 million. It is important to note that IDH's interest bearing debt¹² (excluding accrued interest) decreased during 1H 2025 to reach EGP 179 million as at 30 June 2025, from EGP 265 million at year-end 2024. The decline comes as loans related to Biolab and Al-Borg Scan were successfully repaid.

Interest Expense Breakdown

EGP mn	1H 2024	1H 2025	Change
Interest on Financial Obligations	54	62	15%
Interest Expenses on Leases	13	13	3%
Interest Expenses on Borrowings ¹³	12	11	-13%
Bank Charges	6	11	78%
Fast Track Payment	4	-	-
Total Interest Expense	89	97	9%

Foreign Exchange¹⁴

IDH booked a foreign exchange loss of EGP 3 million in 1H 2025, compared to a foreign exchange gain of EGP 297 million booked during the same period of the previous year. The foreign exchange loss relates to intercompany balances revaluation in entities where the balance was in a currency different to the functional currency.

Taxation

Tax expenses, including income and deferred tax, stood at EGP 342 million in 1H 2025, 65% above last year's first half figure. IDH's effective tax rate increased significantly versus the same period of last year, reaching 37% in 1H 2025 versus 30% this time last year. The increase reflects a normalisation in foreign exchange gain recorded during the period. It is important to highlight that there is no tax payable for IDH's two holding-level companies.



Taxation Breakdown by Region

EGP mn	1H 2024	1H 2025	Change
Egypt	195	330	69%
Jordan	11	8	-27%
Nigeria	0.0	0.2	-
KSA	1	4	308%
Total Tax Expenses	207	342	65%

Net Profit

IDH recorded net profit of EGP 571 million in 1H 2025, up 19% year-on-year. It is worth noting that last year's bottom-line had been significantly boosted by foreign exchange gains booked by the company during 1H 2024. Meanwhile, the Company's NPM came in at 16% in 1H 2025 compared to 19% in the same period of last year.

When controlling for contributions from foreign exchange gains during both years, IDH booked an adjusted net profit of EGP 575 million in 1H 2025, growing 214% year-on-year from EGP 183 million during the first half of last year. The Company's adjusted net profit margin stood at 16% during 1H 2025, up from 7% this time last year.



¹² IDH's interest bearing debt as at 30 June 2025 included EGP 177 million (EGP 91 million as at 30 June 2024) related to its facility with Kuwait Finance House (KFH) – formerly Ahli United Bank (AUB) (outstanding loan balances are excluding accrued interest for the period).

¹³ Interest expenses on medium-term loans include EGP 9 million (EGP 11 million in 1H 2024) related to the Group's facility with Kuwait Finance House (KFH) – formerly Ahli United Bank (AUB).

¹⁴ Foreign exchange gains/losses are included within finance income/costs for both periods.

ii. Balance Sheet Analysis

Assets

Property, Plant and Equipment (PPE)

IDH recorded PPE cost of EGP 3,225 million as at 30 June 2025, up from the EGP 3,104 million as at year-end 2024. The rise in CAPEX as a share of revenue in the six-month period largely reflects the addition of new branches and the renovation of existing branches.

Total CAPEX Addition Breakdown – 1H 2025

EGP mn	1H 2025	% of Revenue
Leasehold Improvements/new branches	120.0	3.4%
Al-Borg Scan Expansion	4.8	0.1%
CAPEX Additions	124.8	3.5%
Translation Effect	(36.2)	-1.0%
Disposals	(18.8)	-0.5%
Total Increase in PPE Cost	69.8	2.0%

Trade Receivables and Provisions


Net trade receivables at 30 June 2025 stood at EGP 963 million, up from EGP 804 million as at year-end 2024. However, IDH's net receivables' Days on Hand booked 129 days, down from 139 days at the end of 2024.

Meanwhile, provision charges for doubtful accounts in 1H 2025 stood at EGP 18 million, largely unchanged compared to EGP 17 million in 1H 2024.

Inventory

At 30 June 2025, IDH booked an inventory balance of EGP 370 million, up 16% compared to inventory booked at year-end 2024. On the other hand, Days Inventory Outstanding (DIO) declined to 94 days, from 105 days at 31 December 2024. The decline in DIO reflects accelerated sales during the second quarter of the year following the seasonal Ramadan slowdown in March.

Cash Balances (EGP mn)



Cash and Net Debt

Cash balances and financial assets at amortised cost at 30 June 2025 reached EGP 1,708 million, down marginally from EGP 1,716 million at year-end 2024.

EGP mn	31 December 2024	30 June 2025
Treasury Bills	74	77
Time Deposits	1,126	820
Current Accounts	494	769
Cash on Hand	23	42
Total	1,716	1,708

IDH's net cash¹⁵ balance recorded EGP 337 million as at 30 June 2025, compared to a net cash of EGP 227 million as at year-end 2024.

¹⁵ The net cash/(debt) balance is calculated as cash and cash equivalent balances including financial assets at amortised cost, less interest-bearing debt (medium term loans), finance lease and right-of-use liabilities.

EGP mn	31 December 2024	30 June 2025	31
Cash and Financial Assets at Amortised Cost ¹⁶	1,716	1,708	
Lease Liabilities Property*	(938)	(935)	
Total Financial Liabilities (Short-term and Long-term)	(269)	(241)	
Interest Bearing Debt ("Medium Term Loans")**	(282)	(194)	
Net Cash/(Debt) Balance	227	337	

Note: Interest Bearing Debt includes accrued interest for each period.

**If excluding Lease Liabilities Property (IFRS 16), IDH would have recorded net cash of EGP 1,273 million.*

***Includes accrued finance cost.*

Lease liabilities and financial obligations on property recorded EGP 935 million at 30 June 2025, largely unchanged versus the figure recorded at year-end 2024.

Meanwhile, **financial obligations related to equipment** recorded at EGP 241 million as at 30 June 2025, with the decline versus the balance at the end of the previous year reflecting a payment of approximately EGP 22 million and the addition of no new contracts in 2025.

Finally, **interest bearing debt**¹⁷ (excluding accrued interest) reached EGP 179 million at the end of the first half of 2025, down from EGP 265 million at year-end 2024. The decline reflects the settlement of the Company's overdraft balance.

Liabilities

Trade Payable¹⁸

Trade payable as of 30 June 2025 stood at EGP 299 million, down from EGP 320 million at the end of 2024. Similarly, Days Payable Outstanding (DPO) came in at 85 days, down from 90 days at 31 December 2024.

Put Option

The put option current liability stood at EGP 733 million as at 30 June 2025, up versus the EGP 532 million at 31 December 2024, and is related to both:

- The option granted in 2011 to Dr. Amid, Biolab's CEO, to sell his stake (40%) to IDH. The put option is in the money and exercisable since 2016 and is calculated as seven times Biolab's LTM EBITDA minus net debt.
- The option granted in 2018 to the International Finance Corporation from Dynasty – shareholders in Echo Lab – and it is exercisable in 2024. The put option is calculated based on fair market value (FMV).

It is important to note that the put option previously included as part of the agreement between IDH, Biolab and Izhoor in Saudi Arabia has been removed following IDH's acquisition of Izhoor's entire 49% stake in Biolab KSA, which was concluded in December 2024. Biolab KSA is now owned 79% by IDH and 21% by its Jordanian subsidiary Biolab.

Dividends

The Board of Directors has recommended that a dividend of USD 10 million, or USD 0.017 per share, should be paid to shareholders who appear on the register as of 12 September 2025, with an ex-dividend date of 11 September 2025. The payment date for the dividend will be 3 October 2025.

¹⁶ It is worth noting that some term deposits and treasury bills cannot be accessed for over three months and are therefore not treated as cash. Term deposits which cannot be accessed for over three months stood at EGP 333 million at 30 June 2025 (2024: EGP 468 million). Meanwhile, treasury bills not accessible for over three months stood at EGP 76 million (2024: EGP 60 million).

¹⁷ IDH's interest bearing debt as at 30 June 2025 included EGP 9 million to its facility with Kuwait Finance House (KFH) – formerly Ahli United Bank (AUB) (outstanding loan balances are excluding accrued interest for the period).

¹⁸ Accounts payable is calculated based on average payables at the end of each period.

Principle Risks and Uncertainties

As in any corporation, IDH has exposure to risks and uncertainties that may adversely affect its performance. The Board and senior management agree that the principal risks and uncertainties facing the Group include political and economic risks in Egypt, the Middle East and Nigeria, foreign currency exchange rate variability and associated risks, changes in regulation and regulatory actions, damage to the Group's reputation, failure to maintain the Group's high quality standards and accreditations, failure to maintain good relationships with healthcare professionals and end users, pricing pressures and business interruption of the Group's testing facilities, among others.

In the short term, other factors influencing the economic landscape include rising geopolitical stability, inflationary pressures in Egypt and Nigeria, and currency devaluation in both countries. These factors may weigh on the cost base in the near future.

Statement of Directors' Responsibilities

Responsibility statement of the directors in respect of the half-yearly financial report

We confirm that to the best of our knowledge, the interim management report includes a fair review of the information required by:

(a) DTR 4.2.7R of the Disclosure Guidance and Transparency Rules, being an indication of important events that have occurred during the first six months of the financial year and their impact on the condensed set of financial statements; and a description of the principal risks and uncertainties for the remaining six months of the year; and

(b) DTR 4.2.8R of the Disclosure Guidance and Transparency Rules, being related party transactions that have taken place in the first six months of the current financial year and that have materially affected the financial position or performance of the entity during that period; and any changes in the related party transactions described in the last annual report that could do so.

For and on behalf of the Board of Directors

Dr. Hend El Sherbini

Executive Director

02 September 2025

INTEGRATED DIAGNOSTICS HOLDINGS plc – “IDH”
AND ITS SUBSIDIARIES

Consolidated Financial Statements

for the six months ended 30 June 2025

Consolidated statement of financial position as at 30 June 2025

	Notes	30 June 2025 EGP'000	31 December 2024 EGP'000
Assets			
Non-current assets			
Property, plant and equipment	4	1,430,969	1,489,647
Intangible assets and goodwill	5	1,872,257	1,806,067
Right of use assets	6	736,136	753,298
Total non-current assets		4,039,362	4,049,012
Current assets			
Inventories		369,656	317,562
Trade and other receivables	8	1,342,994	1,010,605
Financial assets at fair value through profit and loss	7	35,274	36,158
Financial assets at amortized cost	9	408,892	527,832
Cash and cash equivalents	10	1,299,255	1,188,082
Total current assets		3,456,071	3,080,239
Total assets		7,495,433	7,129,251
Equity			
Share capital		1,039,121	1,039,121
Share premium reserve		1,027,706	1,027,706
Capital reserves		(314,310)	(314,310)
Capital Redemption Reserve		33,379	33,379
Legal reserve		51,641	51,641
Put option reserve	12	(732,780)	(532,499)
Translation reserve		(345,139)	(407,595)
Retained earnings		2,364,060	1,812,706
Equity attributable to the owners of the Company		3,123,678	2,710,149
Non-controlling interests		703,991	789,350
Total equity		3,827,669	3,499,499
Non-current liabilities			
Provisions		25,053	23,288
Borrowings	13	26,986	40,479
Other financial obligations	14	921,394	970,890
Deferred tax liabilities	19-C	437,059	431,355
Total non-current liabilities		1,410,492	1,466,012
Current liabilities			
Trade and other payables	11	800,320	826,251
Other financial obligations	14	255,194	236,197
Current put option liability	12	732,780	532,499
Borrowings	13	151,947	224,528
Current tax liabilities		317,031	344,265
Total current liabilities		2,257,272	2,163,740
Total liabilities		3,667,764	3,629,752
Total equity and liabilities		7,495,433	7,129,251

The accompanying notes on pages 23-36 form an integral part of these consolidated financial statements.

These consolidated financial statements were approved and authorised for issue by the Board of Directors and signed on their behalf on 1 September 2025 by:

Dr. Hend El Sherbini
Chief Executive Officer

Sherif El Zeiny
Chief Financial Officer

Consolidated income statement for the six months ended 30 June 2025

	Notes	1H 2025 EGP'000	1H 2024 EGP'000
Revenue	22	3,542,688	2,497,840
Cost of sales		(2,053,405)	(1,572,938)
Gross profit		1,489,283	924,902
Marketing and advertising expenses		(193,302)	(142,075)
Administrative expenses	16	(392,604)	(331,531)
Impairment loss on trade and other receivable		(17,675)	(17,198)
Other income/(expenses)		25,458	838
Operating profit		911,160	434,936
Net fair value losses on financial assets at fair value through profit or loss	17	(4,940)	(10,474)
Finance costs	18	(100,329)	(88,636)
Finance income	18	107,363	351,553
Net finance income/(costs)		7,034	262,917
Profit before income tax		913,254	687,379
Income tax expense	19-B	(341,960)	(207,310)
Profit for the year		571,294	480,069
Profit/(Loss) attributed to:			
Owners of the Company		551,354	530,568
Non-controlling interests		19,940	(50,499)
		571,294	480,069
Earnings per share			
Basic and diluted	21	0.95	0.88

The accompanying notes on pages 23-36 form an integral part of these consolidated financial statements.

Consolidated statement of comprehensive income for the six months ended 30 June 2025

	1H 2025 EGP'000	1H 2024 EGP'000
Net profit for the period	571,294	480,069
Other comprehensive income/(expense):		
Items that may be reclassified to profit or loss:		
Exchange difference on translation of foreign operations	(40,365)	64,160
Other comprehensive income/(expense) for the year, net of tax	(40,365)	64,160
Total comprehensive income for the year	530,929	544,229
Attributable to:		
Owners of the Company	613,810	248,655
Non-controlling interests	(82,881)	295,574
	530,929	544,229

The accompanying notes on pages 23-36 form an integral part of these consolidated financial statements.

Consolidated statement of cash flows for the six months ended 30 June 2025

	Note	1H 2025 EGP'000	1H 2024 EGP'000
Cash flows from operating activities			
Profit for the period before tax		913,254	687,379
Adjustments for:			
Depreciation of property, plant and equipment	4	160,198	146,071
Depreciation of right of use assets	6	97,755	82,201
Amortisation of intangible assets	5	10,567	4,595
Interest income	18	(107,363)	(54,760)
Interest expense	18	85,543	78,554
Bank Charges		11,293	10,081
Loss/(gain) on disposal of PPE		(1,951)	2,651
Impairment in trade and other receivables		17,675	17,198
Equity settled financial assets at fair value		-	(14,977)
ROU Asset/Lease Termination		3,928	(1,575)
Unrealised foreign currency exchange (gains) losses		3,494	(296,793)
FV Through P&L		4,940	10,474
Change in Provisions		1,843	2,877
Change in Inventories		(53,405)	(69,932)
Change in trade and other receivables		(363,436)	(168,206)
Change in trade and other payables		(27,117)	101,474
Cash generated from operating activities before income tax payment		757,218	537,312
Tax paid during the period		(363,171)	(81,883)
Net cash generated from operating activities		394,046	455,430
Cash flows from investing activities			
Interest received on financial asset at amortised cost		115,067	54,925
Payments for the purchase of financial assets at amortized cost		(353,849)	(333,179)
Proceeds for the sale of financial assets at amortized cost		467,317	55,391
Payments for acquisition of property, plant and equipment	4	(112,806)	(70,319)
Payments for acquisition of intangible assets	5	(82,223)	(880)
Proceeds from sale of Property, plant and equipment		3,261	1,067
Payment for purchase of global depository receipts (short-term investment)	17	(55,047)	(151,710)
Proceeds from sale of global depository receipts (short-term investments)	17	50,107	141,236
Net cash used in investing activities		31,828	(303,469)
Cash flows from financing activities			
Proceeds from borrowings		104,962	6,117
Repayments of borrowings		(191,035)	(23,185)
Interest paid		(87,402)	(77,763)
Bank charges paid		(11,293)	(10,081)
Payment of finance lease liabilities		(113,509)	(99,617)
Dividends paid		(2,478)	-
Cash injection by owner of non-controlling interest		-	48,055
Net cash flows used in financing activities		(300,755)	(156,474)
Net increase / (decrease) in cash and cash equivalents		125,120	(4,513)
Cash and cash equivalents at the beginning of the period		1,188,082	674,253
Effect of exchange rate on cash		(13,947)	127,607
Cash and cash equivalents at the end of the period	10	1,299,255	797,347

Non-cash investing and financing activities disclosed in other notes are:

- Acquisition of right-of-use assets – note 6
- Property, plant and equipment – note 4
- Put option liability – note 12

The accompanying notes on pages 23-36 form an integral part of these consolidated financial statements.

Consolidated statement of changes in equity for the six months ended 30 June 2025

EGP'000	Share Capital	Share premium reserve	Capital reserves	Legal reserve*	Capital Redemption Reserve	Put option reserve	Translation reserve	Retained earnings	Total attributed to the owners of the Company	Non-Controlling interests	Total Equity
Balance at 1 January 2025	1,039,121	1,027,706	(314,310)	51,641	33,379	(532,499)	(407,595)	1,812,706	2,710,149	789,350	3,499,499
Profit for the period	-	-	-	-	-	-	-	551,354	551,354	19,940	571,294
Other comprehensive income/(expense) for the period	-	-	-	-	-	-	62,456	-	62,456	(102,821)	(40,365)
Total comprehensive income at 30 June 2025	-	-	-	-	-	-	62,456	551,354	613,810	(82,881)	530,929
Transactions with owners in their capacity as owners											
Contributions and distributions											
Movement in put option liabilities	-	-	-	-	-	(200,281)	-	-	(200,281)	-	(200,281)
Dividends	-	-	-	-	-	-	-	-	-	(2,478)	(2,478)
Total	-	-	-	-	-	(200,281)	-	-	(200,281)	(2,478)	(202,759)
At 30 June 2025 (unaudited)	1,039,121	1,027,706	(314,310)	51,641	33,379	(732,780)	(345,139)	2,364,060	3,123,678	703,991	3,827,669
As at 1 January 2024	1,072,500	1,027,706	(314,310)	51,641	-	(356,583)	(82,341)	1,280,287	2,678,900	421,888	3,100,788
Profit/(loss) for the period	-	-	-	-	-	-	-	530,568	530,568	(50,499)	480,069
Other comprehensive income/(expense) for the year	-	-	-	-	-	-	(281,913)	-	(281,913)	346,073	64,160
Total comprehensive income at 30 June 2024	-	-	-	-	-	-	(281,913)	530,568	248,655	295,574	544,229
Transactions with owners in their capacity as owners											
Contributions and distributions											
Movement in put option liabilities	-	-	-	-	-	(141,255)	-	-	(141,255)	-	(141,255)
Cash injection by owner of non-controlling interest	-	-	-	-	-	-	-	-	-	48,055	48,055
Total	-	-	-	-	-	(141,255)	-	-	(141,255)	48,055	(93,200)
Balance at 30 June 2024 (Unaudited)	1,072,500	1,027,706	(314,310)	51,641	-	(497,838)	(364,254)	1,810,855	2,786,300	765,517	3,551,817

* Under Egyptian Law, each subsidiary in Egypt must set aside at least 5% of its annual net profit into a legal reserve until such time that this represents 50% of each subsidiary's issued capital. This reserve is not distributable to the owners of the Company.

The accompanying notes on pages 23-36 form an integral part of these consolidated financial statements.

1. Reporting entity

Integrated Diagnostics Holdings plc “IDH” or “the Company” is a Company which was incorporated in Jersey on 4 December 2014 and established according to the provisions of the Companies (Jersey) Law 1991 under Registered No. 117257. These condensed consolidated interim financial information as of and for the six months ended 30 June 2025 comprise the Company and its subsidiaries (together referred as the ‘Group’). The Company is a listed entity, in London Stock Exchange (since 2015).

The principal activities of the Company and its subsidiaries (together “The Group”) include investments in all types of the healthcare field of medical diagnostics (the key activities are pathology and Radiology related tests), either through acquisitions of related business in different jurisdictions or through expanding the acquired investments they have. The key jurisdictions that the Group operates are in Egypt, Jordan, Nigeria, Sudan and Saudi Arabia.

The Group’s financial year starts on 1 January and ends on 31 December of each year.

This condensed consolidated interim financial information was approved for issue by the Directors of the Company on 1 September 2025.

2. Basis of preparation

A) Statement of compliance

This condensed consolidated interim financial information has been prepared as per IAS 34 ‘Interim Financial Reporting’ (As adopted by the IASB). as the accounting policies adopted are consistent with those of the previous financial year ended 31 December 2024 and corresponding interim reporting period.

These condensed consolidated interim financial information do not include all the information and disclosures in the annual consolidated financial Statement, and should be read in conjunction with the financial Statement published as at and for the year ended 31 December 2024 which is available at www.idhcorp.com,. In addition, results of the six-month period ended 30 June 2025 are not necessary indicative for the results that may be expected for the financial year ending 31 December 2024.

B) Basis of measurement

The condensed consolidated interim financial information has been prepared on the historical cost basis except where adopted IFRS mandates that fair value accounting is required which is related to the financial assets and liabilities measured at fair value.

C) Functional and presentation currency

This condensed consolidated interim financial information is presented in Egyptian Pounds (EGP’000). The functional currency of the majority of the Group’s entities is the Egyptian Pound (EGP) and is the currency of the primary economic environment in which the Group operates.

The Group also operates in Jordan, Sudan, Nigeria and Saudi Arabia and the functional currencies of those foreign operations are the local currencies of those respective territories, however due to the size of these operations, there is no significant impact on the functional currency of the Group, which is the Egyptian Pound (EGP).

3. Significant accounting policies

In preparing these condensed consolidated interim financial information, the significant judgments made by the management in applying the Group’s accounting policies and the key sources of estimation uncertainty were the same as those that were applied to the consolidated financial statements for the year ended 31 December 2024. “The preparation of these condensed consolidated interim financial information requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expense. Actual results may differ from these estimates. Information about significant areas of estimation uncertainty and critical judgement in applying accounting policies that have the most significant effect on the amount recognised in the condensed consolidated interim financial statement is described in note 3.2 of the annual consolidated financial statements published for the year ended 31 December 2024. In preparing this condensed consolidated interim financial information, the significant judgments made by the management in applying the Group’s accounting policies and the key sources of estimation uncertainty were the same as those that were applied to the consolidated financial statements for the year ended 31 December 2024”.

4. Property, plant and equipment

	Land & buildings	Medical, & electric equipment	Leasehold improvements	Fixtures, fittings & vehicles	Building & Leasehold improvements in construction	Payment on account	Total
Cost							
Balance at 1 January 2025	492,937	1,514,724	859,460	215,236	21,633	7,135	3,111,125
Additions	-	73,222	16,374	8,826	14,196	188	112,806
Disposals	-	(3,727)	(324)	(2,621)	-	-	(6,672)
Exchange differences	(1,867)	(22,173)	(8,863)	(3,267)	-	-	(36,170)
Transfers	-	-	12,177	-	(12,177)	-	-
Balance at 30 June 2025	491,070	1,562,046	878,824	218,174	23,652	7,323	3,181,089
Depreciation							
Balance at 1 January 2025	80,871	900,326	522,467	117,814	-	-	1,621,478
Depreciation for the period	4,371	85,924	58,949	10,954	-	-	160,198
Disposals	-	(2,608)	(318)	(2,436)	-	-	(5,362)
Exchange differences	(238)	(19,126)	(4,600)	(2,230)	-	-	(26,194)
Balance at 30 June 2025	85,004	964,516	576,498	124,102	-	-	1,750,120
Net book amount							
At 30 June 2025 (Unaudited)	406,066	597,530	302,326	94,072	23,652	7,323	1,430,969
At 31 December 2024	412,066	614,398	336,993	97,422	21,633	7,135	1,489,647

5. Intangible assets and goodwill

Intangible assets represent goodwill acquired through business combinations and brand names.

	Goodwill	Brand name	Software	Total
Cost				
Balance at 1 January 2025	1,363,277	429,109	128,710	1,921,096
Additions	-	-	82,223	82,223
Exchange differences	(3,829)	(1,598)	(880)	(6,307)
Balance at 30 June 2025	1,359,448	427,511	210,053	1,997,012
Amortisation				
Balance at 1 January 2025	17,242	367	97,420	115,029
Amortisation	-	-	10,567	10,567
Exchange differences	(171)	(1)	(669)	(841)
Balance at 30 June 2025	17,071	366	107,318	124,755
Net book amount				
At 30 June 2025 (Unaudited)	1,342,377	427,145	102,735	1,872,257
At 31 December 2024	1,346,035	428,742	31,290	1,806,067

Goodwill impairment reviews are undertaken annually or more frequently if events or changes in circumstances indicate a potential impairment. No indicators of impairment have been identified during the six months ended 30 June 2025.

6. Right-of-use assets

	30 June 2025 (Unaudited)	31 December 2024 (Audited)
Balance at 1 January	753,298	683,025
Addition for the period / year	94,145	109,710
Depreciation charge for the period / year	(97,755)	(173,655)
Terminated contracts	(5,206)	(18,288)
Exchange differences	(8,346)	152,506
	736,136	753,298

7. Financial asset at fair value through profit or loss

	30 June 2025	31 December 2024
	(Unaudited)	(Audited)
Current equity investments	35,274	36,158
	35,274	36,158

- * On August 17, 2017, Al Makhbaryoun Al Arab (seller) has signed IT purchase Agreement with JSC Mega Lab (Buyer) to transfer and install the Laboratory Information Management System (LIMS) for a purchase price amounted to USD 400,000, which will be in the form of 10% equity stake in JSC Mega Lab. In case the valuation of the project is less or more than USD 4,000,000, the seller stake will be adjusted accordingly, in a way that the seller equity stake shall not fall below 5% of JSC Mega Lab.
- Ownership percentage in JSC Mega Lab at the transaction date on April 8, 2019, and as of June 30, 2025, was 8.25%.
 - On April 8, 2019, Al Mokhabariyoun Al Arab (Biolab) has signed a Shareholder Agreement with JSC Mega Lab and JSC Georgia Healthcare Group (CHG), whereas, BioLab Shall have a put option, exercisable within 12 months immediately after the expiration of five (5) year period from the signing date, which allows BioLab stake to be bought out by CHG at a price of the equity value of BioLab Shares/total stake (being USD 400,000) plus 15% annual IRR (including preceding 5 Financial years). After the expiration of above 12 months from the date of the put option period expiration, which allows CHG to purchase Biolab's all shares at a price of equity value of Biolab's stake (having value of USD 400,000) plus higher of 20% annual IRR or 6X EV/EBITDA (of the financial year immediately preceding the call option exercise date). In case the Management Agreement or the Purchase Agreement and/or the SLA is terminated/cancelled within 6 months period from the date of such termination/cancellation, CHG shall have a call option, which allows the CHG to purchase Biolab's all Shares at a price of the equity value of BioLab's stake in JSC Mega Lab (having value of USD 400,000) plus 20% annual IRR. If JCI accreditation is not obtained, immediately after the expiration of the additional 12 months period of the CHG shall have a call option (the Accreditation Call option), exercisable within 6 months period, which allows CHG to purchase BioLab's all Shares at a price of the equity value of BioLab's stake in JSC Mega Lab (having value of USD 400,000) plus 20% annual IRR.

8. Trade and other receivables

	30 June 2025	31 December 2024
	(Unaudited)	(Audited)
Trade receivables – net	963,181	804,081
Prepayments	128,350	80,297
Due from related parties note (15)	6,268	5,543
Other receivables	140,867	108,652
Accrued revenue	4,328	12,032
Down payment for Cairo Ray acquisition*	100,000	-
	1,342,994	1,010,605

* Other receivables contain EGP 100 M paid for Cairo Ray acquisition as a first instalment.

The expected credit loss related to trade and other receivables was EGP 225,446 K (2024: EGP 208,476 K). Below shows the movements in the provision for impairment of trade and other receivables:

	30 June 2025	31 December 2024
	(Unaudited)	(Audited)
Balance at 1 January	208,476	191,580
Charge for the period	17,675	48,312
Utilised	-	(41,567)
Exchange differences	(705)	10,151
	225,446	208,476

9. Financial assets at amortised cost

	30 June 2025	31 December 2024
	(Unaudited)	(Audited)
Term deposits (more than 3 months)	333,046	468,142
Treasury bills (more than 3 months)	75,846	59,690
	408,892	527,832

The maturity date of the treasury bills and Fixed-term deposits are between more than 3 months and 12 months and have average interest rates before tax on treasury bills of EGP 29.00% Fixed-term deposits more than 3 months have average interest rates of EGP and USD 4% respectively and Fixed-term deposits more than 3 months have average interest rates of EGP and JOD 5.54% and 5.38% respectively.

10. Cash and cash equivalents

	30 June 2025	31 December 2024
	(Unaudited)	(Audited)
Cash at banks and on hand	811,073	516,318
Treasury bills (less than 3 months)	1,150	14,358
Term deposits (less than 3 months)	487,032	657,406
	1,299,255	1,188,082

Cash at banks earns interest at floating rates based on daily bank deposit rates. Short-term deposits and treasury bills are made for varying periods of between one day and three months, depending on the immediate cash requirements of the Group, and earn interest at the respective weighted average rate. Of the above Short-term deposits relate to amounts held in Egypt with a weighted average rate of 19.50% (2024: 22.65%), Short-term deposits relate to amounts held in Dubai with a weighted average rate of 4.10%, Short-term deposits relate to amounts held in Jordan with a weighted average rate of 5.2% (2024: 4.86%) and Short-term deposits relate to amounts held in Mauritius with a weighted average rate of 4.30% (2024: 4.80%) and Treasury bills are denominated in EGP and earn interest at a weighted average rate before tax of 26.20% (2024: 24.95%) per annum.

11. Trade and other payables

	30 June 2025	31 December 2024
	(Unaudited)	(Audited)
Trade payables	298,511	320,068
Accrued expenses	220,603	246,523
Due to related parties note (15)	22,766	28,654
Other payables	131,515	125,935
Deferred revenue	120,415	96,410
Accrued finance cost	6,510	8,661
	800,320	826,251

12. Put option liability

	30 June 2025	31 December 2024
	(Unaudited)	(Audited)
Current put option - Al Makhbaryoun Al Arab (Biolab)	713,267	512,577
Current put option - Eagle Eye-Echo scan	19,513	19,922
	732,780	532,499

Put option - Biolab Jordan

The accounting policy for put options after initial recognition is to recognise all changes in the carrying value of the put option liability within equity.

Through the historic acquisitions of Makhbaryoun Al Arab the Group entered into separate put option arrangements to purchase the remaining equity interests from the vendors at of a subsequent date. At acquisition, a put option liability has been recognised at the net present value of the exercise price of the option. The option is calculated at seven times EBITDA of the last 12 months minus Net Debt and its exercisable in whole starting the fifth anniversary of completion of the original purchase agreement, which fell due in June 2016. The vendor has not exercised this right on 30 June 2025. It is important to note that the put option liability is treated as current as it could be exercised at any time by the NCI. However, based on discussions and ongoing business relationships, there is no expectation that this will happen in the next 18 months the option has no expiry date.

Put option - Eagle Eye-Echo scan

IFC has the option to put its shares according to definitive agreements signed on 15 January 2018 between Dynasty group Holdings Limited and International Finance Corporation (IFC) related to the Eagle Eye-Echo Scan Limited transaction, IFC has the option to put it shares to Dynasty group Holdings Limited in year 2025. The put option price will be calculated on the basis of the fair market value determined by an independent valuer.

13. Loans and borrowings

	Currency	Nominal Interest rate	Maturity	30 June 2025 (Unaudited)	31 December 2024 (Audited)
Kuwait Finance Bank (AUB – Previously)	EGP	CBE corridor rate*+1%	26 January 2027	53,972	67,465
Kuwait Finance Bank (AUB – Previously)**	EGP	CBE corridor rate*+0.75%	31 May 2030	100,000	-
Kuwait Finance Bank (AUB – Previously)	EGP	Secured 5%	3 April 2026	22,902	17,940
			30 November 2025	-	
Mashreq Bank	USD	Secured 2%			162,474
		Secured		2,059	
Bank Al Etihad	JOD	11.75%	15 July 2025		17,128
				178,933	265,007
<u>Amount held as:</u>					
Current liability				151,947	224,528
Non-current liability				26,986	40,479
				178,933	265,007

* As at 30 June 2025, corridor rate 25.00% (2024: 28.25%)

** During the period the company signed medium-term loan amounting to EGP 400 M to finance the investment cost for Cairo ray for radiotherapy acquisition, as of 30 June 2025 the company had drawn down EGP 100 M from the total facility available, the loan will be fully repaid by May 2030.

- A)** In July 2018, AL-Borg lab, one of IDH subsidiaries, was granted a medium term loan amounting to EGP 130.5m from Kuwait Finance Bank (AUB – Previously) to finance the investment cost related to the expansion into the radiology segment. As at 30 June 2025, only EGP 124.9M had been drawn down from the total facility available with EGP 70.9M repaid. The loan will be fully repaid by January 2027.

The loan contains the following financial covenants which if breached will mean the loan is repayable on demand:

- The financial leverage shall not exceed 0.7 throughout the period of the loan.
“**Financial leverage**”: total bank debt divided by net equity.
- The debt service ratios (DSR) shall not be less than **1.35 starting 2020**
“**Debt service ratio**”: cash operating profit after tax plus depreciation for the financial year less annual maintenance on machinery and equipment adding cash balance (cash and cash equivalent) divided by total financial payments.

“**Cash operating profit**”: Operating profit after tax, interest expense, depreciation and amortisation, is calculated as follows: Net income after tax and unusual items adding Interest expense, Depreciation, Amortisation and provisions excluding tax related provisions less interest income and Investment income and gains from extraordinary items.

“**Financial payments**”: current portion of long-term debt including finance lease payments, interest expense and fees and dividends distributions.

- The current ratios shall not be less than 1.
“**Current ratios**”: Current assets divided current liabilities.

AL- Borg company didn’t breach any covenants for MTL agreements.

14. Other financial obligations

Future minimum financial obligation payments under leases and sales purchase contracts, together with the present value of the net minimum lease payments are, as follows:

	30 June 2025	31 December 2024
	(Unaudited)	(Audited)
*Financial liability – laboratory equipment	241,180	263,892
*Lease liabilities – building	935,408	943,195
	1,176,588	1,207,087

*The financial obligation liabilities for the laboratory equipment and building are payable as follows:

	30 June 2025		
	Minimum payments (Unaudited)	Interest (Unaudited)	Principal (Unaudited)
Less than one year	384,141	128,947	255,194
Between one and five years	1,065,044	313,197	751,847
More than five years	225,163	55,616	169,547
	1,674,348	497,760	1,176,588

	31 December 2024		
	Minimum payments (Audited)	Interest (Audited)	Principal (Audited)
Less than one year	372,329	136,132	236,197
Between one and five years	1,104,329	308,544	795,785
More than Five years	230,185	55,080	175,105
	1,706,843	499,756	1,207,087

Amounts recognised in profit or loss:

	30 June	
	2025 (Unaudited)	2024 (Unaudited)
Interest on lease liabilities	62,053	53,829
Expenses related to short-term lease	4,366	3,200

15. Related party transactions

The significant transactions with related parties, their nature volumes and balance during the period 30 June 2025 are as follows:

Related Party	Nature of transaction	Nature of relationship	30 June 2025	
			Transaction amount of the period	Amount due from / (to)
			EGP'000	EGP'000
International Fertility (IVF)**	Expenses paid on behalf	Affiliate	4	15
H.C Security	Provide service	Entity owned by Company's board member	(7)	(80)
Life Health Care	Provided service	Entity owned by Company's CEO	342	1,037
Dr. Amid Abd Elnour	Put option liability	Bio. Lab C.E.O and shareholder	(200,690)	(713,267)
	Current account	Bio. Lab C.E.O and shareholder	15,626	(4,057)
	Accrued share-based payment	Bio. Lab C.E.O and shareholder	(9,947)	(9,947)
International Finance corporation (IFC)	Put option liability	Echo-Scan shareholder	408	(19,513)
Integrated Treatment for Kidney Diseases (S.A.E)	Rental income	Entity owned by Company's CEO	212	-
	Medical Test analysis		591	5,216
Hena Holdings Ltd	shareholders' dividends deferral agreement	Shareholder	119	(4,760)
Actis IDH Limited	shareholders' dividends deferral agreement	Shareholder	97	(3,922)
				(749,278)

Related Party	Nature of transaction	Nature of relationship	31 December 2024	
			Transaction amount of the year	Amount due from / (to)
			EGP'000	EGP'000
International Fertility (IVF)**	Expenses paid on behalf	Affiliate	11	11
H.C Security	Provide service	Entity owned by Company's board member	20	(73)
Life Health Care	Provided service	Entity owned by Company's CEO	(2,677)	695
Dr. Amid Abd Elnour	Put option liability	Bio. Lab C.E.O and shareholder	(211,194)	(512,577)
	Current account	Bio. Lab C.E.O and shareholder	(19,217)	(19,683)
International Finance corporation (IFC)	Put option liability	Echo-Scan shareholder	(7,508)	(19,921)
Integrated Treatment for Kidney Diseases (S.A.E)	Rental income	Entity owned by Company's CEO	(2,582)	4,837
	Medical Test analysis		591	-
HENA HOLDINGS LTD	shareholders' dividends deferral agreement	Shareholder	(1,916)	(4,879)
ACTIS IDH LIMITED	shareholders' dividends deferral agreement	Shareholder	(1,579)	(4,019)
				(555,609)

* International Fertility (IVF) is a company whose shareholders include Dr. Moamena Kamel (founder of IDH subsidiary Al-Mokhtabar Labs).

Compensation of key management personnel of the Group

The amounts disclosed in the table are the amounts recognised as an expense during the reporting period related to key management personnel.

	30 June 2025 (Unaudited)	30 June 2024 (Unaudited)
Short-term employee benefits	64,231	43,463
	64,231	43,463

16. General and administrative expenses

	For the six months ended 30 June	
	2025	2024
	(Unaudited)	(Unaudited)
Wages and salaries	206,765	135,287
Depreciation	14,474	16,726
Amortisation	4,896	4,134
Consulting fees	53,516	102,942
Share based payment*	9,947	-
Other expenses	103,006	72,442
Total	392,604	331,531

* During the period the company charged expenses with EGP 9.9 M due to contract signed with Dr. Amid Abdelnour is hereby allocated shadow shares from Medical health development company (KSA) shares equivalent to 4% of the shares of the issued and paid-up share capital of the company, from time to time, in two equal rounds: 2% on 31 December 2024 (First Round Shadow Shares) 2% on 31 December 2025 (Second Round Shadow Shares), the value of the calculations based on company valuation. As of 30 June 2025, the amount (EGP 9.9 million) remains accrued.

17. Net fair value losses on financial assets at fair value through profit or loss

During the first half of 2025, Integrated Diagnostics Holdings Limited company invested in Global Depositary Receipt (GDR) tradable in stock exchanges, where the companies purchased 2.740 million shares, EGP 55 M from the Egyptian Stock Exchange and sold them during the same period on the London Stock exchange at USD 1.03 M excluding the transaction cost.

		Number of shares'000	2025	2024
			EGP'000	EGP'000
			(Unaudited)	(Unaudited)
listed equity securities	Shares bought	2,740	(55,047)	(151,710)
	Shares sale	2,740	50,107	141,236
			(4,940)	(10,474)

18. Net finance cost

	For the six months ended 30 June	
	2025 (Unaudited)	2024 (Unaudited)
Finance income		
Interest income	107,363	54,760
Net foreign exchange gain	-	296,793
Total finance income	107,363	351,553
Finance cost		
Fast Track Payment	-	(3,736)
Net foreign exchange (loss)	(3,493)	-
Bank charges	(11,293)	(6,346)
Interest expense	(85,543)	(78,554)
Total finance cost	(100,329)	(88,636)
Net finance income	7,034	262,917

19. Tax expense

Tax expense is recognised based on management's best estimate of the weighted-average annual income tax rate expected for the full financial year multiplied by the pre-tax income of the interim reporting period.

A) Income tax

Amounts recognised in profit or loss as follows:

	For the six months ended 30 June	
	2025 (Unaudited)	2024 (Unaudited)
Current tax:		
Current tax	(267,449)	(149,628)
Deferred tax:		
Deferred tax arising on undistributed reserves in subsidiaries	(66,852)	(55,063)
Deferred tax relating to origination and reversal of temporary differences	(7,659)	(2,619)
Total Deferred tax expense	(74,511)	(57,682)
Tax expenses recognised in profit or loss	(341,960)	(207,310)

B) Deferred tax liabilities

Deferred tax relates to the following:

	30 June 2025 (Unaudited)	31 December 2024 (Audited)
Property, plant and equipment	(46,745)	(38,224)
Intangible assets	(119,135)	(120,077)
Undistributed reserves from Group subsidiaries	(273,667)	(275,542)
Provisions	2,488	2,488
Net deferred tax liabilities	(437,059)	(431,355)

20. Financial instruments

The Group has reviewed the financial assets and liabilities held at 30 June 2025. It has been deemed that the carrying amounts for all financial instruments are a reasonable approximation of fair value. All financial instruments are deemed Level 3.

21. Earnings per share

	For the six months ended 30 June	
	2025 (Unaudited)	2024 (Unaudited)
Profit attributed to owners of the parent	552,198	530,568
Weighted average number of ordinary shares in issue	581,326	600,000
Basic and diluted earnings per share	0.95	0.88

On 18 September 2024, Integrated Diagnostics Holding PLC Company “IDH” Purchased a total of 18,673,728 treasury shares at a total amount of EGP 374.4 million, all of these treasury shares were cancelled on 8 October 2024.

The Company has no potential diluted shares as at 30 June 2025 and 30 June 2024, therefore the earnings per diluted share are equivalent to basic earnings per share.

22. Segment reporting

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker. The chief operating decision-maker who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the steering committee that makes strategic decisions.

The Group has five operating segments based on geographical location, as the Group’s Chief Operating Decision Maker (CODM) reviews the internal management reports and KPIs of each geography.

The Group operates in five geographic areas, Egypt, Sudan, Jordan, Nigeria and Saudi Arabia. As a provider of medical diagnostic services, IDH’s operations in Sudan are not subject to sanctions. The revenue split, EBITDA split (being the key profit measure reviewed by CODM) net profit and loss between the five regions is set out below.

For the six months ended	Revenue split by geographic location					
	Egypt region	Sudan region	Jordan region	Nigeria region	Saudi Arabia	Total
30 June 2025 (Unaudited)	2,965,813	1,451	492,535	57,562	25,327	3,542,688
30 June 2024 (Unaudited)	2,069,240	-	385,837	38,517	4,246	2,497,840

For the six months ended	Adjusted EBITDA by split geographic location					
	Egypt region	Sudan region	Jordan region	Nigeria region	Saudi Arabia	Total
30 June 2025 (Unaudited)	1,072,046	(14)	141,767	1,347	(25,519)	1,189,627
30 June 2024 (Unaudited)	691,994	(44)	88,712	(13,455)	(70,016)	697,191

For the six months ended	Net profit / (loss) split by geographic location					
	Egypt region	Sudan region	Jordan region	Nigeria region	Saudi Arabia	Total
30 June 2025 (Unaudited)	554,246	20,650	48,366	(2,906)	(49,062)	571,294
30 June 2024 (Unaudited)	560,010	11,033	5,343	(11,916)	(84,401)	480,069

	Non-current assets by geographic location					
	Egypt region	Sudan region	Jordan region	Nigeria region	Saudi Arabia	Total
30 June 2025 (Unaudited)	3,087,618	2,316	839,119	30,488	79,821	4,039,362
31 December 2024	3,037,039	2,374	883,309	35,808	90,482	4,049,012

The operating segment profit measure reported to the CODM is EBITDA, as follows:

	For the six months ended 30 June	
	2025 (Unaudited)	2024 (Unaudited)
Profit from operations	911,160	434,936
Property, plant and equipment depreciation	160,198	146,071
Right of use depreciation	97,755	82,201
Amortization of Intangible assets	10,567	4,595
EBITDA	1,179,680	667,803
Non-recurring expenses (Note 16)	9,947	29,388
Normalised EBITDA	1,189,627	697,191

23 . Distributions made and proposed

	30-Jun-25	30-Jun-24
	EGP'000	EGP'000
After the balance sheet date, the following dividends were proposed by the directors (the dividends have not been provided for):	495,476	-
US\$ 0.017 per share (2024: nil) per share	495,476	-

The proposed 2025 dividend on ordinary shares are subject to approval at the annual general meeting and is not recognised as a liability as at 30 Jun 2025.

24. Significant events during the period

- On 19 June 2025, the company acquired Cairo Ray for Radiotherapy for a total acquisition cost of EGP 400 M, which allows the group to grow its radiology portfolio and the company is in the process of preparing the purchase price allocation study to be finalized by the end of the third quarter.
- The Monetary Policy Committee (MPC) of the Central Bank of Egypt (CBE) decided to decrease the overnight deposit rate, overnight lending rate, and the rate of the main operation by 225 basis points on 17 April 2025, bringing them to 25.00%, 26.00%, and 25.50%, respectively. Subsequently, on 22 May 2025, the MPC implemented a further 100 basis point cut, reducing the rates to 24.00%, 25.00%, and 24.50%. Most recently, on 28 August 2025, the Committee decided to decrease the rates by an additional 200 basis points, setting the overnight deposit rate at 22.00%, the overnight lending rate at 23.00%, and the rate of the main operation at 22.50%.